Alx Oncology Holdings (ALXO) Gains from Sales and Divestitures (2022 - 2025)
Alx Oncology Holdings recorded quarterly Gains from Sales and Divestitures of $280308.0 in Q4 2025, down 23.82% quarter-over-quarter from $367932.0 in Q4 2024, and down 23.82% year-over-year from $367932.0 in Q4 2024.
Alx Oncology Holdings' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $280308.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures fell 23.82% year-over-year to $280308.0; the TTM figure through Dec 2025 stood at $280308.0 (down 23.82% YoY), while the FY2025 annual figure was $280308.0, down 23.82% from the prior year.
- Gains from Sales and Divestitures came in at $280308.0 for Q4 2025 at Alx Oncology Holdings, down from $367932.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $367932.0 in Q4 2024 to a low of $1888.0 in Q1 2022.
- A 4-year average of $142763.6 and a median of $53774.0 in 2022 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures surged 439.02% in 2023 and fell 23.82% in 2025, its largest moves.
- Alx Oncology Holdings' Gains from Sales and Divestitures stood at $53774.0 in 2022, then soared by 439.02% to $289854.0 in 2023, then rose by 26.94% to $367932.0 in 2024, then dropped by 23.82% to $280308.0 in 2025.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $280308.0, $367932.0, and $289854.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 280,308.00 |
| Dec 31, 2025 | 280,308.00 |
| Dec 31, 2024 | 367,932.00 |
| Dec 31, 2024 | 367,932.00 |
| Dec 31, 2023 | 289,854.00 |
| Dec 31, 2023 | 289,854.00 |
| Dec 31, 2022 | 53,774.00 |
| Dec 31, 2022 | 53,774.00 |
| Sep 30, 2022 | 3,701.00 |
| Sep 30, 2022 | 3,701.00 |
| Jun 30, 2022 | 1,888.00 |
| Jun 30, 2022 | 1,888.00 |
| Mar 31, 2022 | 1,888.00 |
| Mar 31, 2022 | 1,888.00 |